
Amaxa Biosystems
Proprietary non-viral gene transfer technology for cells.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor | €0.0 | round |
N/A | €0.0 | round | |
N/A | Acquisition | ||
Total Funding | 000k |

Related Content
In the world of biotech research, getting new genetic material into a cell is a fundamental challenge. In 1998, a company was founded in Cologne, Germany, to tackle this problem head-on. Amaxa Biosystems set out to improve on existing methods, which were often inefficient, especially for the sensitive primary cells that are critical for modern research. Their breakthrough was a novel electroporation-based method called Nucleofector technology. First introduced in 2001, this system used a specific combination of electrical pulses and specialized solutions to deliver substrates like DNA and RNA not just into the cell's cytoplasm, but directly into the nucleus. This was a significant step forward, allowing researchers to transfect even non-dividing cells like neurons and resting T-cells with high efficiency. The technology opened up new avenues for disease research, gene therapies, and stem cell work. For a decade, Amaxa grew, establishing itself as a leader in its niche. The value of its unique technology did not go unnoticed. In July 2008, the Swiss life sciences giant Lonza Group completed its acquisition of Amaxa. The move integrated Amaxa's team and its powerful Nucleofector platform into Lonza's broader cell discovery business, strengthening its position in the market.